BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzo A, Ricci AD, Brandi G. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun 2021;27:100337. [PMID: 33611090 DOI: 10.1016/j.ctarc.2021.100337] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Rizzo A, Ricci AD, Brandi G. Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? Expert Review of Precision Medicine and Drug Development 2021;6:217-24. [DOI: 10.1080/23808993.2021.1915126] [Reference Citation Analysis]
2 Chakrabarti S, Finnes HD, Mahipal A. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management. Expert Opinion on Drug Metabolism & Toxicology. [DOI: 10.1080/17425255.2022.2039118] [Reference Citation Analysis]
3 Popescu V, Kanhaiya K, Năstac DI, Czeizler E, Petre I. Network controllability solutions for computational drug repurposing using genetic algorithms. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-05335-3] [Reference Citation Analysis]
4 Rizzo A, Ricci AD, Gadaleta-caldarola G, Brandi G. Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies. Expert Review of Precision Medicine and Drug Development. [DOI: 10.1080/23808993.2021.2008144] [Reference Citation Analysis]
5 Rizzo A. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. Medicina (Kaunas) 2021;57:458. [PMID: 34066684 DOI: 10.3390/medicina57050458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Weng Q, Tan W, Yu RY, Xu RA, Chen Y. A novel bioanalytical method for the quantification of pemigatinib in rat plasma by UPLC-MS/MS. J Pharm Biomed Anal 2021;202:114137. [PMID: 34015593 DOI: 10.1016/j.jpba.2021.114137] [Reference Citation Analysis]
7 Ji T, Rockich K, Epstein N, Overholt H, Wang P, Chen X, Punwani N, Yeleswaram S. Evaluation of drug-drug interactions of pemigatinib in healthy participants. Eur J Clin Pharmacol 2021. [PMID: 34282472 DOI: 10.1007/s00228-021-03184-z] [Reference Citation Analysis]
8 Beri N. Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. Future Oncol 2022. [PMID: 35081733 DOI: 10.2217/fon-2021-1089] [Reference Citation Analysis]
9 Rizzo A, Ricci AD, Cusmai A, Acquafredda S, De Palma G, Brandi G, Palmiotti G. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. Current Oncology 2022;29:551-64. [DOI: 10.3390/curroncol29020050] [Reference Citation Analysis]
10 Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol 2022. [PMID: 35510484 DOI: 10.2217/fon-2022-0214] [Reference Citation Analysis]
11 Ceci L, Zhou T, Lenci I, Meadows V, Kennedy L, Li P, Ekser B, Milana M, Zhang W, Wu C, Sato K, Chakraborty S, Glaser SS, Francis H, Alpini G, Baiocchi L. Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development. Cancers 2022;14:1442. [DOI: 10.3390/cancers14061442] [Reference Citation Analysis]
12 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities? Expert Rev Gastroenterol Hepatol 2021;15:1239-40. [PMID: 34449276 DOI: 10.1080/17474124.2021.1974296] [Reference Citation Analysis]
13 Ji T, Chen X, Liu X, Yeleswaram S. Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies. Clinical Pharm in Drug Dev. [DOI: 10.1002/cpdd.1038] [Reference Citation Analysis]
14 Rizzo A, Ricci AD. Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon? Expert Review of Precision Medicine and Drug Development 2022;7:50-7. [DOI: 10.1080/23808993.2022.2075724] [Reference Citation Analysis]
15 Yu J, Mahipal A, Kim R. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. Onco Targets Ther 2021;14:5145-60. [PMID: 34720591 DOI: 10.2147/OTT.S272208] [Reference Citation Analysis]
16 Rizzo A, Dadduzio V, Lombardi L, Ricci AD, Gadaleta-Caldarola G. Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges. Curr Oncol 2021;28:3393-402. [PMID: 34590592 DOI: 10.3390/curroncol28050293] [Reference Citation Analysis]